L
Lisa M. Coussens
Researcher at Oregon Health & Science University
Publications - 266
Citations - 71080
Lisa M. Coussens is an academic researcher from Oregon Health & Science University. The author has contributed to research in topics: Immune system & Cancer. The author has an hindex of 88, co-authored 232 publications receiving 60476 citations. Previous affiliations of Lisa M. Coussens include Genentech & Icahn School of Medicine at Mount Sinai.
Papers
More filters
Journal ArticleDOI
Inflammation and cancer
Lisa M. Coussens,Zena Werb +1 more
TL;DR: It is now becoming clear that the tumour microenvironment, which is largely orchestrated by inflammatory cells, is an indispensable participant in the neoplastic process, fostering proliferation, survival and migration.
Journal ArticleDOI
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Douglas Hanahan,Lisa M. Coussens +1 more
TL;DR: Most of the hallmarks of cancer are enabled and sustained to varying degrees through contributions from repertoires of stromal cell types and distinctive subcell types, which presents interesting new targets for anticancer therapy.
Journal ArticleDOI
Understanding the tumor immune microenvironment (TIME) for effective therapy.
Mikhail Binnewies,Edward W. Roberts,Kelly Kersten,Vincent Chan,Douglas F. Fearon,Miriam Merad,Lisa M. Coussens,Dmitry I. Gabrilovich,Suzanne Ostrand-Rosenberg,Suzanne Ostrand-Rosenberg,Catherine C. Hedrick,Robert H. Vonderheide,Mikael J. Pittet,Rakesh K. Jain,Weiping Zou,T. Kevin Howcroft,Elisa C. Woodhouse,Robert A. Weinberg,Matthew F. Krummel +18 more
TL;DR: By parsing the unique classes and subclasses of tumor immune microenvironment (TIME) that exist within a patient’s tumor, the ability to predict and guide immunotherapeutic responsiveness will improve, and new therapeutic targets will be revealed.
Journal ArticleDOI
Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
Vancheswaran Gopalakrishnan,Vancheswaran Gopalakrishnan,Christine N. Spencer,Christine N. Spencer,Luigi Nezi,Alexandre Reuben,Miles C. Andrews,Tatiana Karpinets,Peter A. Prieto,D. Vicente,K. Hoffman,Spencer C. Wei,Alexandria P. Cogdill,Li Zhao,Courtney W. Hudgens,Diane S. Hutchinson,T. Manzo,M. Petaccia de Macedo,Tiziana Cotechini,T. Kumar,Wei Shen Chen,Sangeetha M. Reddy,R. Szczepaniak Sloane,Jessica Galloway-Peña,Hong Jiang,P. L. Chen,Elizabeth J. Shpall,Katayoun Rezvani,Amin M. Alousi,Roy F. Chemaly,Samuel A. Shelburne,Luis M Vence,Pablo C. Okhuysen,V. B. Jensen,Alton G. Swennes,Florencia McAllister,E. Marcelo Riquelme Sanchez,Yu Zhang,Laurence Zitvogel,Nicolas Pons,Jacob Austin-Breneman,Lauren E. Haydu,Elizabeth M. Burton,J. M. Gardner,E. Sirmans,Jing Shan Hu,Alexander J. Lazar,Takahiro Tsujikawa,Adi Diab,Hussein Abdul-Hassan Tawbi,Isabella C. Glitza,Wen-Jen Hwu,Sapna Pradyuman Patel,Scott E. Woodman,Rodabe N. Amaria,Michael A. Davies,Jeffrey E. Gershenwald,Patrick Hwu,J. E. Lee,Jianhua Zhang,Lisa M. Coussens,Zachary A. Cooper,P.A. Futreal,Carrie R. Daniel,Carrie R. Daniel,Nadim J. Ajami,Joseph F. Petrosino,Michael T. Tetzlaff,Pradeep Sharma,James P. Allison,Robert R. Jenq,Jennifer A. Wargo +71 more
TL;DR: Examination of the oral and gut microbiome of melanoma patients undergoing anti-programmed cell death 1 protein (PD-1) immunotherapy suggested enhanced systemic and antitumor immunity in responding patients with a favorable gut microbiome as well as in germ-free mice receiving fecal transplants from responding patients.
Journal ArticleDOI
Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations
TL;DR: The studies that brought MPIs into clinical testing are reviewed and the design and outcome of the trials are discussed in light of new information about the cellular source, substrates, and mode of action of MMPs at different stages of tumor progression.